Randy A. Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Randy A. Jones has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Virginia LeBaron
University of Virginia School of Nursing
7 shared publications - Emmanuel Ogunjirin
University of Virginia School of Engineering & Applied Science Charlottesville, VA United States
6 shared publications - James Hayes
University of Virginia School of Engineering & Applied Science Charlottesville, VA United States
6 shared publications - John Lach
The George Washington University School of Engineering & Applied Science Washington, DC United States
6 shared publications - Kate Gordon
Virginia Commonwealth University Health Richmond, VA United States
6 shared publications - Leslie Blackhall
University of Virginia School of Medicine Charlottesville, VA United States
6 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- p. 1-9
Socioeconomic and Health Pathways Linking Race/Ethnicity to Prostate Cancer Severity: A Structural Equation Modeling Analysis
Objectives: Prostate cancer screening guidelines emphasize shared decision-making, yet these decisions are shaped by structural contexts. While racial and ethnic disparities in outcomes are well-documented, the socioeconomic and pre-diagnostic health pathways driving these differences in later life remain unclear. This study utilized structural equation modeling (SEM) to evaluate whether socioeconomic status (SES) and pre-diagnostic health profiles mediate the relationship between race/ethnicity and clinical severity at prostate cancer diagnosis. Methods: We analyzed 5,438 men aged 55 to 74 years diagnosed with prostate cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Parallel mediation SEM with weighted least squares estimation examined two pathways linking race/ethnicity to latent clinical severity (prostate-specific antigen (PSA), Gleason score, and stage): SES pathway and a pre-diagnostic health profile pathway (PSA screening history, comorbidity, and family history). Results: The baseline latent severity model demonstrated acceptable fit (CFI = 0.872, TLI = 0.872, RMSEA = 0.034, SRMR = 0.027). Neither SES nor the measured pre-diagnostic health profile meaningfully mediated racial/ethnic differences in clinical severity. Compared with White men, total effects on latent clinical severity were significant only for AsAm men (0.465, 95% CI: 0.256 to 0.642). Predicted latent severity was highest among Asian men (1.659), followed by Black (1.155) and Hispanic (1.076). Conclusions: These findings suggest that unmeasured mechanisms remain poorly understood in explaining racial and ethnic disparities in prostate cancer severity. Future studies incorporating richer social determinants measures and greater inclusion of underrepresented racial and ethnic groups may clarify pathways underlying these disparities.
- 7 November 2026
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- p. 1-9
Open AccessSocioeconomic and Health Pathways Linking Race/Ethnicity to Prostate Cancer Severity: A Structural Equation Modeling Analysis
Objectives: Prostate cancer screening guidelines emphasize shared decision-making, yet these decisions are shaped by structural contexts. While racial and ethnic disparities in outcomes are well-documented, the socioeconomic and pre-diagnostic health pathways driving these differences in later life remain unclear. This study utilized structural equation modeling (SEM) to evaluate whether socioeconomic status (SES) and pre-diagnostic health profiles mediate the relationship between race/ethnicity and clinical severity at prostate cancer diagnosis. Methods: We analyzed 5,438 men aged 55 to 74 years diagnosed with prostate cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Parallel mediation SEM with weighted least squares estimation examined two pathways linking race/ethnicity to latent clinical severity (prostate-specific antigen (PSA), Gleason score, and stage): SES pathway and a pre-diagnostic health profile pathway (PSA screening history, comorbidity, and family history). Results: The baseline latent severity model demonstrated acceptable fit (CFI = 0.872, TLI = 0.872, RMSEA = 0.034, SRMR = 0.027). Neither SES nor the measured pre-diagnostic health profile meaningfully mediated racial/ethnic differences in clinical severity. Compared with White men, total effects on latent clinical severity were significant only for AsAm men (0.465, 95% CI: 0.256 to 0.642). Predicted latent severity was highest among Asian men (1.659), followed by Black (1.155) and Hispanic (1.076). Conclusions: These findings suggest that unmeasured mechanisms remain poorly understood in explaining racial and ethnic disparities in prostate cancer severity. Future studies incorporating richer social determinants measures and greater inclusion of underrepresented racial and ethnic groups may clarify pathways underlying these disparities.
- 29 May 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (6)
Developing the multidisciplinary and multispecialty workforce and the systems needed to sustain high-quality care from diagnosis through long-term survivorship
With the growing population of individuals living with and beyond cancer-who often have a variety of complex health needs across their lifetimes-coordinated multidisciplinary, multispecialty expert care is needed to ensure comprehensive survivorship cancer care beginning at diagnosis. Guided by the July 2023 US National Academies of Sciences, Engineering, and Medicine workshop, we describe the evidence and propose steps to (1) identify and promote clinician competencies through education and training; (2) improve communication and care coordination, including leveraging the electronic health record and digital health innovations; (3) examine health system interventions and financial strategies to facilitate multidisciplinary, multispecialty survivorship care; and (4) identify policy, payment, and advocacy challenges and opportunities to achieve equitable, accessible, high-quality care. Although the recommendations are centered on the United States, their applicability to other countries should also be explored.
- 29 May 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (6)
Developing the multidisciplinary and multispecialty workforce and the systems needed to sustain high-quality care from diagnosis through long-term survivorship
With the growing population of individuals living with and beyond cancer-who often have a variety of complex health needs across their lifetimes-coordinated multidisciplinary, multispecialty expert care is needed to ensure comprehensive survivorship cancer care beginning at diagnosis. Guided by the July 2023 US National Academies of Sciences, Engineering, and Medicine workshop, we describe the evidence and propose steps to (1) identify and promote clinician competencies through education and training; (2) improve communication and care coordination, including leveraging the electronic health record and digital health innovations; (3) examine health system interventions and financial strategies to facilitate multidisciplinary, multispecialty survivorship care; and (4) identify policy, payment, and advocacy challenges and opportunities to achieve equitable, accessible, high-quality care. Although the recommendations are centered on the United States, their applicability to other countries should also be explored.
- Open Access
- 16 May 2026
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
Shared Decision-Making for Prostate Cancer Screening in Racial and Ethnic Minority Populations: A Systematic Review
Objectives: Prostate cancer screening (PCS) remains controversial in its efficacy, making shared decision-making (SDM) essential to ensure informed choices. However, racial and ethnic minority men in the United States experience persistent disparities in PCS participation and outcomes. Despite these disparities, how SDM interventions have been designed, implemented, and evaluated for these populations remains unclear. To address this gap, this systematic review examined SDM interventions for PCS among minority men, with a specific focus on the extent to which interventions incorporated key SDM features (information exchange, deliberation, and decision implementation). Method: Six databases (PubMed, Embase, CINAHL, PsycINFO, Web of Science, and Scopus) were used to search for U.S.-based, English-language studies published in the past ten years. We included studies that evaluated SDM interventions for PCS among racial and ethnic minority men. Results: Eighteen studies met the inclusion criteria. Most targeted African American men, with limited racial/ethnic diversity. The majority of interventions were delivered as single-session programs. While all studies supported information exchange, few incorporated the full spectrum of SDM components. Outcome measures were inconsistent across studies, and critical variables relevant to minority populations, such as trust in healthcare, were not assessed. Conclusions: These findings illustrate ongoing challenges in both the design and evaluation of SDM interventions, including limited application of core SDM features and lack of population diversity. This review calls for future studies to develop and test culturally adapted, multi-component SDM interventions. Such efforts are needed to advance SDM research and ultimately contribute to more equitable, patient-centered cancer care.
- 16 May 2026
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
Open AccessShared Decision-Making for Prostate Cancer Screening in Racial and Ethnic Minority Populations: A Systematic Review
Objectives: Prostate cancer screening (PCS) remains controversial in its efficacy, making shared decision-making (SDM) essential to ensure informed choices. However, racial and ethnic minority men in the United States experience persistent disparities in PCS participation and outcomes. Despite these disparities, how SDM interventions have been designed, implemented, and evaluated for these populations remains unclear. To address this gap, this systematic review examined SDM interventions for PCS among minority men, with a specific focus on the extent to which interventions incorporated key SDM features (information exchange, deliberation, and decision implementation). Method: Six databases (PubMed, Embase, CINAHL, PsycINFO, Web of Science, and Scopus) were used to search for U.S.-based, English-language studies published in the past ten years. We included studies that evaluated SDM interventions for PCS among racial and ethnic minority men. Results: Eighteen studies met the inclusion criteria. Most targeted African American men, with limited racial/ethnic diversity. The majority of interventions were delivered as single-session programs. While all studies supported information exchange, few incorporated the full spectrum of SDM components. Outcome measures were inconsistent across studies, and critical variables relevant to minority populations, such as trust in healthcare, were not assessed. Conclusions: These findings illustrate ongoing challenges in both the design and evaluation of SDM interventions, including limited application of core SDM features and lack of population diversity. This review calls for future studies to develop and test culturally adapted, multi-component SDM interventions. Such efforts are needed to advance SDM research and ultimately contribute to more equitable, patient-centered cancer care.
- 15 November 2025
- Published by Elsevier in Nursing Outlook
- Vol. 73 (6) , 102594
Engaging transgender and gender-expansive adults in qualitative research studies
- 15 November 2025
- Published by Elsevier in Nursing Outlook
- Vol. 73 (6) , 102594
Engaging transgender and gender-expansive adults in qualitative research studies
- 7 April 2025
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 76, 102891
Cancer patient-family caregiver mutuality: A concept analysis
- 7 April 2025
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 76, 102891
Cancer patient-family caregiver mutuality: A concept analysis
- 31 December 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (1) , 1-12
Exploration of shared decision making in oncology within the United States: a scoping review
Purpose Shared decision making (SDM) among the oncology population is highly important due to complex screening and treatment decisions. SDM among patients with cancer, caregivers, and clinicians has gained more attention and importance, yet few articles have systematically examined SDM, specifically in the adult oncology population. This review aims to explore SDM within the oncology literature and help identify major gaps and concerns, with the goal to provide guidance in the development of clear SDM definitions and interventions. Methods We conducted a scoping review using the Arksey and O’Malley approach along with the PRISMA Extension for Scoping Reviews Checklist. A systematic search was conducted in four databases that included publications since 2016. Results Of the 364 initial articles, eleven publications met the inclusion criteria. We included articles that were original research, cancer related, and focused on shared decision making. Most studies were limited in defining SDM and operationalizing a model of SDM. There were several concerns revealed related to SDM: (1) racial inequality, (2) quality and preference of the patient, caregiver, and clinician communication is important, and (3) the use of a decision-making aid or tool provides value to the patient experience. Conclusion Inconsistencies regarding the meaning and operationalization of SDM and inequality of the SDM process among patients from different racial/ethnic backgrounds impact the health and quality of care patients receive. Future studies should clearly and consistently define the meaning of SDM and develop decision aids that incorporate bidirectional, interactive communication between patients, caregivers, and clinicians that account for the diversity of racial, ethnic, and sociocultural backgrounds and preferences.
- 31 December 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (1) , 1-12
Exploration of shared decision making in oncology within the United States: a scoping review
Purpose Shared decision making (SDM) among the oncology population is highly important due to complex screening and treatment decisions. SDM among patients with cancer, caregivers, and clinicians has gained more attention and importance, yet few articles have systematically examined SDM, specifically in the adult oncology population. This review aims to explore SDM within the oncology literature and help identify major gaps and concerns, with the goal to provide guidance in the development of clear SDM definitions and interventions. Methods We conducted a scoping review using the Arksey and O’Malley approach along with the PRISMA Extension for Scoping Reviews Checklist. A systematic search was conducted in four databases that included publications since 2016. Results Of the 364 initial articles, eleven publications met the inclusion criteria. We included articles that were original research, cancer related, and focused on shared decision making. Most studies were limited in defining SDM and operationalizing a model of SDM. There were several concerns revealed related to SDM: (1) racial inequality, (2) quality and preference of the patient, caregiver, and clinician communication is important, and (3) the use of a decision-making aid or tool provides value to the patient experience. Conclusion Inconsistencies regarding the meaning and operationalization of SDM and inequality of the SDM process among patients from different racial/ethnic backgrounds impact the health and quality of care patients receive. Future studies should clearly and consistently define the meaning of SDM and develop decision aids that incorporate bidirectional, interactive communication between patients, caregivers, and clinicians that account for the diversity of racial, ethnic, and sociocultural backgrounds and preferences.
- Open Access
- 9 August 2022
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 8 (3) , e36879
Deploying the Behavioral and Environmental Sensing and Intervention for Cancer Smart Health System to Support Patients and Family Caregivers in Managing Pain: Feasibility and Acceptability Study
Background: Distressing cancer pain remains a serious symptom management issue for patients and family caregivers, particularly within home settings. Technology can support home-based cancer symptom management but must consider the experience of patients and family caregivers, as well as the broader environmental context. Objective: This study aimed to test the feasibility and acceptability of a smart health sensing system—Behavioral and Environmental Sensing and Intervention for Cancer (BESI-C)—that was designed to support the monitoring and management of cancer pain in the home setting. Methods: Dyads of patients with cancer and their primary family caregivers were recruited from an outpatient palliative care clinic at an academic medical center. BESI-C was deployed in each dyad home for approximately 2 weeks. Data were collected via environmental sensors to assess the home context (eg, light and temperature); Bluetooth beacons to help localize dyad positions; and smart watches worn by both patients and caregivers, equipped with heart rate monitors, accelerometers, and a custom app to deliver ecological momentary assessments (EMAs). EMAs enabled dyads to record and characterize pain events from both their own and their partners’ perspectives. Sensor data streams were integrated to describe and explore the context of cancer pain events. Feasibility was assessed both technically and procedurally. Acceptability was assessed using postdeployment surveys and structured interviews with participants. Results: Overall, 5 deployments (n=10 participants; 5 patient and family caregiver dyads) were completed, and 283 unique pain events were recorded. Using our “BESI-C Performance Scoring Instrument,” the overall technical feasibility score for deployments was 86.4 out of 100. Procedural feasibility challenges included the rurality of dyads, smart watch battery life and EMA reliability, and the length of time required for deployment installation. Postdeployment acceptability Likert surveys (1=strongly disagree; 5=strongly agree) found that dyads disagreed that BESI-C was a burden (1.7 out of 5) or compromised their privacy (1.9 out of 5) and agreed that the system collected helpful information to better manage cancer pain (4.6 out of 5). Participants also expressed an interest in seeing their own individual data (4.4 out of 5) and strongly agreed that it is important that data collected by BESI-C are shared with their respective partners (4.8 out of 5) and health care providers (4.8 out of 5). Qualitative feedback from participants suggested that BESI-C positively improved patient-caregiver communication regarding pain management. Importantly, we demonstrated proof of concept that seriously ill patients with cancer and their caregivers will mark pain events in real time using a smart watch. Conclusions: It is feasible to deploy BESI-C, and dyads find the system acceptable. By leveraging human-centered design and the integration of heterogenous environmental, physiological, and behavioral data, the BESI-C system offers an innovative approach to monitor cancer pain, mitigate the escalation of pain and distress, and improve symptom management self-efficacy. International Registered Report Identifier (IRRID): RR2-10.2196/16178
- 9 August 2022
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 8 (3) , e36879
Open AccessDeploying the Behavioral and Environmental Sensing and Intervention for Cancer Smart Health System to Support Patients and Family Caregivers in Managing Pain: Feasibility and Acceptability Study
Background: Distressing cancer pain remains a serious symptom management issue for patients and family caregivers, particularly within home settings. Technology can support home-based cancer symptom management but must consider the experience of patients and family caregivers, as well as the broader environmental context. Objective: This study aimed to test the feasibility and acceptability of a smart health sensing system—Behavioral and Environmental Sensing and Intervention for Cancer (BESI-C)—that was designed to support the monitoring and management of cancer pain in the home setting. Methods: Dyads of patients with cancer and their primary family caregivers were recruited from an outpatient palliative care clinic at an academic medical center. BESI-C was deployed in each dyad home for approximately 2 weeks. Data were collected via environmental sensors to assess the home context (eg, light and temperature); Bluetooth beacons to help localize dyad positions; and smart watches worn by both patients and caregivers, equipped with heart rate monitors, accelerometers, and a custom app to deliver ecological momentary assessments (EMAs). EMAs enabled dyads to record and characterize pain events from both their own and their partners’ perspectives. Sensor data streams were integrated to describe and explore the context of cancer pain events. Feasibility was assessed both technically and procedurally. Acceptability was assessed using postdeployment surveys and structured interviews with participants. Results: Overall, 5 deployments (n=10 participants; 5 patient and family caregiver dyads) were completed, and 283 unique pain events were recorded. Using our “BESI-C Performance Scoring Instrument,” the overall technical feasibility score for deployments was 86.4 out of 100. Procedural feasibility challenges included the rurality of dyads, smart watch battery life and EMA reliability, and the length of time required for deployment installation. Postdeployment acceptability Likert surveys (1=strongly disagree; 5=strongly agree) found that dyads disagreed that BESI-C was a burden (1.7 out of 5) or compromised their privacy (1.9 out of 5) and agreed that the system collected helpful information to better manage cancer pain (4.6 out of 5). Participants also expressed an interest in seeing their own individual data (4.4 out of 5) and strongly agreed that it is important that data collected by BESI-C are shared with their respective partners (4.8 out of 5) and health care providers (4.8 out of 5). Qualitative feedback from participants suggested that BESI-C positively improved patient-caregiver communication regarding pain management. Importantly, we demonstrated proof of concept that seriously ill patients with cancer and their caregivers will mark pain events in real time using a smart watch. Conclusions: It is feasible to deploy BESI-C, and dyads find the system acceptable. By leveraging human-centered design and the integration of heterogenous environmental, physiological, and behavioral data, the BESI-C system offers an innovative approach to monitor cancer pain, mitigate the escalation of pain and distress, and improve symptom management self-efficacy. International Registered Report Identifier (IRRID): RR2-10.2196/16178
- Open Access
- 9 February 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Results from feasibility and acceptability testing of Behavioral and Environmental Sensing and Intervention for Cancer (BESI-C): A smart health sensing system to support patients and family caregivers in managing cancer pain. (Preprint)
BACKGROUND Distressing cancer pain remains a serious symptom management issue for patients and family caregivers, especially in the home setting. Technology can support home-based cancer symptom management but must consider the experience of both patients and family caregivers, as well as the broader environmental context. OBJECTIVE To test feasibility and acceptability of a smart health sensing system, Behavioral and Environmental Sensing and Intervention for Cancer (BESI-C), designed to monitor, and ultimately support management of, cancer pain in the home setting. METHODS Dyads of patients with cancer and their primary family caregivers were recruited from an outpatient palliative care clinic at an academic medical center in the Southeastern U.S. BESI-C was deployed in dyad homes for approximately two weeks each. Data were collected via: 1) environmental sensors that measure ambient noise, humidity, barometric pressure, light, and temperature; 2) Bluetooth beacons to help localize dyad position; and 3) smart watches worn by both patients and caregivers equipped with heartrate monitors, accelerometers, and a custom application to deliver ecological momentary assessments (EMAs). EMAs enabled dyads to record and characterize pain events from both their own and their partner’s perspective. Sensor data streams were integrated to describe and explore the context for cancer pain events. Feasibility was assessed technically (by scoring each deployment regarding fidelity of data capture across system components) and procedurally (e.g., deployment process, participant recruitment). Acceptability was assessed by post-deployment surveys and structured interviews with participants. RESULTS 5 deployments (n=10 participants; 5 dyads of patients and primary family caregivers) were completed, and a total of 283 unique pain events were recorded. Using our ‘BESI-C Performance Scoring Instrument’, the overall feasibility technical score for deployments was 86.4/100. Procedural feasibility challenges included: rural location of dyads; smart watch battery life and EMA reliability; and length of time required for deployment installation. Post-deployment acceptability Likert surveys (1, strongly disagree; 5, strongly agree), found dyads disagreed that BESI-C was a burden (1.7/5) or compromised their privacy (1.9/5) and agreed the system collected helpful information to better manage cancer pain (4.6/5). Participants also expressed interest in seeing their own individual data (4.4/5) and strongly agreed it is important that data collected by BESI-C are shared with their respective partner (4.8/5) and healthcare provider (4.8/5). Qualitative feedback from participants suggests BESI-C positively improved communication regarding pain management. Importantly, we demonstrated proof of concept that seriously ill patients and their caregivers will mark pain events in real time using a smart watch. CONCLUSIONS It is feasible to deploy BESI-C, and dyads find the system acceptable. Leveraging human-centered design and the collection of heterogenous environmental, physiological, and behavioral data, BESI-C offers an innovative approach to monitor cancer pain, mitigate escalation of pain and distress, and improve symptom management self-efficacy. Future work will: (shorter-term) 1) test BESI-C in a larger, more diverse sample; 2) continue to streamline system architecture; 3) deploy a no-contact, self-installation system in response to the COVID-19 pandemic and to enhance scalability; 4) explore how to best share data visualizations of collected data with key stakeholders; and 5) (longer-term) inform design of and deliver just-in-time personalized pain management interventions to patients and caregivers. CLINICALTRIAL n/a INTERNATIONAL REGISTERED REPORT RR2-10.2196/16178
- 9 February 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessResults from feasibility and acceptability testing of Behavioral and Environmental Sensing and Intervention for Cancer (BESI-C): A smart health sensing system to support patients and family caregivers in managing cancer pain. (Preprint)
BACKGROUND Distressing cancer pain remains a serious symptom management issue for patients and family caregivers, especially in the home setting. Technology can support home-based cancer symptom management but must consider the experience of both patients and family caregivers, as well as the broader environmental context. OBJECTIVE To test feasibility and acceptability of a smart health sensing system, Behavioral and Environmental Sensing and Intervention for Cancer (BESI-C), designed to monitor, and ultimately support management of, cancer pain in the home setting. METHODS Dyads of patients with cancer and their primary family caregivers were recruited from an outpatient palliative care clinic at an academic medical center in the Southeastern U.S. BESI-C was deployed in dyad homes for approximately two weeks each. Data were collected via: 1) environmental sensors that measure ambient noise, humidity, barometric pressure, light, and temperature; 2) Bluetooth beacons to help localize dyad position; and 3) smart watches worn by both patients and caregivers equipped with heartrate monitors, accelerometers, and a custom application to deliver ecological momentary assessments (EMAs). EMAs enabled dyads to record and characterize pain events from both their own and their partner’s perspective. Sensor data streams were integrated to describe and explore the context for cancer pain events. Feasibility was assessed technically (by scoring each deployment regarding fidelity of data capture across system components) and procedurally (e.g., deployment process, participant recruitment). Acceptability was assessed by post-deployment surveys and structured interviews with participants. RESULTS 5 deployments (n=10 participants; 5 dyads of patients and primary family caregivers) were completed, and a total of 283 unique pain events were recorded. Using our ‘BESI-C Performance Scoring Instrument’, the overall feasibility technical score for deployments was 86.4/100. Procedural feasibility challenges included: rural location of dyads; smart watch battery life and EMA reliability; and length of time required for deployment installation. Post-deployment acceptability Likert surveys (1, strongly disagree; 5, strongly agree), found dyads disagreed that BESI-C was a burden (1.7/5) or compromised their privacy (1.9/5) and agreed the system collected helpful information to better manage cancer pain (4.6/5). Participants also expressed interest in seeing their own individual data (4.4/5) and strongly agreed it is important that data collected by BESI-C are shared with their respective partner (4.8/5) and healthcare provider (4.8/5). Qualitative feedback from participants suggests BESI-C positively improved communication regarding pain management. Importantly, we demonstrated proof of concept that seriously ill patients and their caregivers will mark pain events in real time using a smart watch. CONCLUSIONS It is feasible to deploy BESI-C, and dyads find the system acceptable. Leveraging human-centered design and the collection of heterogenous environmental, physiological, and behavioral data, BESI-C offers an innovative approach to monitor cancer pain, mitigate escalation of pain and distress, and improve symptom management self-efficacy. Future work will: (shorter-term) 1) test BESI-C in a larger, more diverse sample; 2) continue to streamline system architecture; 3) deploy a no-contact, self-installation system in response to the COVID-19 pandemic and to enhance scalability; 4) explore how to best share data visualizations of collected data with key stakeholders; and 5) (longer-term) inform design of and deliver just-in-time personalized pain management interventions to patients and caregivers. CLINICALTRIAL n/a INTERNATIONAL REGISTERED REPORT RR2-10.2196/16178
- Open Access
- 16 September 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-12
Employing a mobile health decision aid to improve decision-making for patients with advanced prostate cancer and their decision partners/proxies: the CHAMPION randomized controlled trial study design
Background: Metastatic prostate cancer remains a lethal malignancy that warrants novel supportive interventions for patients and their decision partners and proxies. Decision aids have been applied primarily to patients with localized disease, with minimal inclusion of patients with advanced prostate cancer and their decision partners. The use of a community patient navigator (CPN) has been shown to have a positive supportive role in health care, particularly with individuals from minority populations. Research is needed to evaluate decision support interventions tailored to the needs of advanced prostate cancer patients and their decision partners in diverse populations. Methods: Guided by Janis and Mann’s Conflict Model of Decision Making, the Cancer Health Aid to Manage Preferences and Improve Outcomes through Navigation (CHAMPION) is a randomized controlled trial to assess the feasibility and acceptability of a mobile health (mHealth), CPN-administered decision support intervention designed to facilitate communication between patients, their decision partners, and the healthcare team. Adult prostate cancer patients and their decision partners at three mid-Atlantic hospitals in the USA were randomized to receive enhanced usual care or the decision intervention. The CHAMPION intervention includes a theory-based decision-making process tutorial, immediate and health-related quality of life graphical summaries over time (using mHealth), values clarification via a balance sheet procedure with the CPN support during difficult decisions, and facilitated discussions with providers to enhance informed, shared decision-making. Discussion: The CHAMPION intervention is designed to leverage dynamic resources, such as CPN teams, mHealth technology, and theory-based information, to support decision-making for advanced prostate cancer patients and their decision partners. This intervention is intended to engage decision partners in addition to patients and represents a novel, sustainable, and scalable way to build on individual and community strengths. Patients from minority populations, in particular, may face unique challenges during clinical communication. CHAMPION emphasizes the inclusion of decision partners and CPNs as facilitators to help address these barriers to care. Thus, the CHAMPION intervention has the potential to positively impact patient and decision partner well-being by reducing decisional conflict and decision regret related to complex, treatment-based decisions, and to reduce cancer health disparities. Trial registration ClinicalTrials.gov NCT03327103. Registered on 31 October 2017—retrospectively registered. World Health Organization Trial Registration Data Set included in Supplementary Materials.
- 16 September 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-12
Open AccessEmploying a mobile health decision aid to improve decision-making for patients with advanced prostate cancer and their decision partners/proxies: the CHAMPION randomized controlled trial study design
Background: Metastatic prostate cancer remains a lethal malignancy that warrants novel supportive interventions for patients and their decision partners and proxies. Decision aids have been applied primarily to patients with localized disease, with minimal inclusion of patients with advanced prostate cancer and their decision partners. The use of a community patient navigator (CPN) has been shown to have a positive supportive role in health care, particularly with individuals from minority populations. Research is needed to evaluate decision support interventions tailored to the needs of advanced prostate cancer patients and their decision partners in diverse populations. Methods: Guided by Janis and Mann’s Conflict Model of Decision Making, the Cancer Health Aid to Manage Preferences and Improve Outcomes through Navigation (CHAMPION) is a randomized controlled trial to assess the feasibility and acceptability of a mobile health (mHealth), CPN-administered decision support intervention designed to facilitate communication between patients, their decision partners, and the healthcare team. Adult prostate cancer patients and their decision partners at three mid-Atlantic hospitals in the USA were randomized to receive enhanced usual care or the decision intervention. The CHAMPION intervention includes a theory-based decision-making process tutorial, immediate and health-related quality of life graphical summaries over time (using mHealth), values clarification via a balance sheet procedure with the CPN support during difficult decisions, and facilitated discussions with providers to enhance informed, shared decision-making. Discussion: The CHAMPION intervention is designed to leverage dynamic resources, such as CPN teams, mHealth technology, and theory-based information, to support decision-making for advanced prostate cancer patients and their decision partners. This intervention is intended to engage decision partners in addition to patients and represents a novel, sustainable, and scalable way to build on individual and community strengths. Patients from minority populations, in particular, may face unique challenges during clinical communication. CHAMPION emphasizes the inclusion of decision partners and CPNs as facilitators to help address these barriers to care. Thus, the CHAMPION intervention has the potential to positively impact patient and decision partner well-being by reducing decisional conflict and decision regret related to complex, treatment-based decisions, and to reduce cancer health disparities. Trial registration ClinicalTrials.gov NCT03327103. Registered on 31 October 2017—retrospectively registered. World Health Organization Trial Registration Data Set included in Supplementary Materials.
- Open Access
- 26 August 2020
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 4 (8) , e20836
Understanding the Experience of Cancer Pain From the Perspective of Patients and Family Caregivers to Inform Design of an In-Home Smart Health System: Multimethod Approach
Background: Inadequately managed pain is a serious problem for patients with cancer and those who care for them. Smart health systems can help with remote symptom monitoring and management, but they must be designed with meaningful end-user input. Objective: This study aims to understand the experience of managing cancer pain at home from the perspective of both patients and family caregivers to inform design of the Behavioral and Environmental Sensing and Intervention for Cancer (BESI-C) smart health system. Methods: This was a descriptive pilot study using a multimethod approach. Dyads of patients with cancer and difficult pain and their primary family caregivers were recruited from an outpatient oncology clinic. The participant interviews consisted of (1) open-ended questions to explore the overall experience of cancer pain at home, (2) ranking of variables on a Likert-type scale (0, no impact; 5, most impact) that may influence cancer pain at home, and (3) feedback regarding BESI-C system prototypes. Qualitative data were analyzed using a descriptive approach to identity patterns and key themes. Quantitative data were analyzed using SPSS; basic descriptive statistics and independent sample t tests were run. Results: Our sample (n=22; 10 patient-caregiver dyads and 2 patients) uniformly described the experience of managing cancer pain at home as stressful and difficult. Key themes included (1) unpredictability of pain episodes; (2) impact of pain on daily life, especially the negative impact on sleep, activity, and social interactions; and (3) concerns regarding medications. Overall, taking pain medication was rated as the category with the highest impact on a patient’s pain (=4.79), followed by the categories of wellness (=3.60; sleep quality and quantity, physical activity, mood and oral intake) and interaction (=2.69; busyness of home, social or interpersonal interactions, physical closeness or proximity to others, and emotional closeness and connection to others). The category related to environmental factors (temperature, humidity, noise, and light) was rated with the lowest overall impact (=2.51). Patients and family caregivers expressed receptivity to the concept of BESI-C and reported a preference for using a wearable sensor (smart watch) to capture data related to the abrupt onset of difficult cancer pain. Conclusions: Smart health systems to support cancer pain management should (1) account for the experience of both the patient and the caregiver, (2) prioritize passive monitoring of physiological and environmental variables to reduce burden, and (3) include functionality that can monitor and track medication intake and efficacy; wellness variables, such as sleep quality and quantity, physical activity, mood, and oral intake; and levels of social interaction and engagement. Systems must consider privacy and data sharing concerns and incorporate feasible strategies to capture and characterize rapid-onset symptoms.
- 26 August 2020
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 4 (8) , e20836
Open AccessUnderstanding the Experience of Cancer Pain From the Perspective of Patients and Family Caregivers to Inform Design of an In-Home Smart Health System: Multimethod Approach
Background: Inadequately managed pain is a serious problem for patients with cancer and those who care for them. Smart health systems can help with remote symptom monitoring and management, but they must be designed with meaningful end-user input. Objective: This study aims to understand the experience of managing cancer pain at home from the perspective of both patients and family caregivers to inform design of the Behavioral and Environmental Sensing and Intervention for Cancer (BESI-C) smart health system. Methods: This was a descriptive pilot study using a multimethod approach. Dyads of patients with cancer and difficult pain and their primary family caregivers were recruited from an outpatient oncology clinic. The participant interviews consisted of (1) open-ended questions to explore the overall experience of cancer pain at home, (2) ranking of variables on a Likert-type scale (0, no impact; 5, most impact) that may influence cancer pain at home, and (3) feedback regarding BESI-C system prototypes. Qualitative data were analyzed using a descriptive approach to identity patterns and key themes. Quantitative data were analyzed using SPSS; basic descriptive statistics and independent sample t tests were run. Results: Our sample (n=22; 10 patient-caregiver dyads and 2 patients) uniformly described the experience of managing cancer pain at home as stressful and difficult. Key themes included (1) unpredictability of pain episodes; (2) impact of pain on daily life, especially the negative impact on sleep, activity, and social interactions; and (3) concerns regarding medications. Overall, taking pain medication was rated as the category with the highest impact on a patient’s pain (=4.79), followed by the categories of wellness (=3.60; sleep quality and quantity, physical activity, mood and oral intake) and interaction (=2.69; busyness of home, social or interpersonal interactions, physical closeness or proximity to others, and emotional closeness and connection to others). The category related to environmental factors (temperature, humidity, noise, and light) was rated with the lowest overall impact (=2.51). Patients and family caregivers expressed receptivity to the concept of BESI-C and reported a preference for using a wearable sensor (smart watch) to capture data related to the abrupt onset of difficult cancer pain. Conclusions: Smart health systems to support cancer pain management should (1) account for the experience of both the patient and the caregiver, (2) prioritize passive monitoring of physiological and environmental variables to reduce burden, and (3) include functionality that can monitor and track medication intake and efficacy; wellness variables, such as sleep quality and quantity, physical activity, mood, and oral intake; and levels of social interaction and engagement. Systems must consider privacy and data sharing concerns and incorporate feasible strategies to capture and characterize rapid-onset symptoms.